Lodonal™ is Immune Therapeutics, Inc.’s approved immune modulator for use in emerging nations. Lodonal™, based on the Low Dose Naltrexone formulation, IRT-103/Lodonal™ currently in use with Immune’s wholly owned subsidiary Cytocom, Inc. is designed to offer affordable immune modulation in countries exhibiting the most need for improved health with low cost while developing their own advanced health care systems. Currently, Lodonal™ has received approval in Nigeria following a successful bridging trial.
Met-enkephalin, some times referred to as Opioid Growth Factor (OGF) have been studied by a number of scientists but the most published of these are Dr. Ian Zagon and his team from Pennsylvania State Medical Center at Hershey extensively in relationship to growth – especially in cancer and Dr. Nicholas Plotnikoff in conjunction with. Bihari and Dr. Ronald Herberman and Robert Good in the treatment of HIV/AIDS and cancer. Much of this research has been carried out in the USA, Belgium, Croatia and Germany.
Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s wholly owned subsidiary Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial. More information can be found at www.cytocom.com
Immune Therapeutics Inc. recently acquired the Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and therapeeutic clinical data from Super-T Cell Cancer Company (“STCC”) a newly formed corporation.